Dr Jammi Nagaraj Rao

2 Articles Published | Follow:

Itolizumab: Why Real-World Data Can’t Substitute Randomised Controlled Trials

Is Biocon’s Itolizumab Good News? Hard to Tell, Thanks to the Bad Science.